Last reviewed · How we verify
NCT03662295
Stroke-like Migraine Attacks After Radiation Treatment (SMART) Syndrome Language Intervention
trial testing Language treatment in Migraine Disorders in 1 participant. Completed in 13 November 2019.
13 November 2019
Quick facts
| Lead sponsor | Quality Living, Inc. |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 1 |
| Start date | 3 September 2018 |
| Primary completion | 13 November 2019 |
| Estimated completion | 13 November 2019 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Language treatment
Conditions studied
- Migraine Disorders — all drugs for Migraine Disorders →
- Aphasia — all drugs for Aphasia →
Sponsor
Quality Living, Inc.
Who can join
Adults 19 to 65, any sex, with Migraine Disorders or Aphasia. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Stroke-like migraine attacks after radiation therapy-also known as SMART syndrome-constitute a rare condition typically characterized by headache, seizures, vision abnormalities, hemiparesis, and aphasia. The condition usually resolves within a few days or weeks of onset with no residual impairments. However, resolution in some cases extends over a period of months rather than weeks and may be incomplete. The purpose of this case report is to provide an in-depth description of the progression of changes in cognitive and language functioning for a person exhibiting SMART syndrome characterized by slow recovery.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT03662295
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Migraine Disorders
Currently open trials in the same condition.
- NCT07170176 — Effects of PFO Closure on Glymphatic Function and Clinical Symptoms in Patients With Migraine · NA · recruiting
- NCT07093138 — Evaluation of Efficacy and Safety of Topical Cannabidiol (Canvert-M Produced by Alasht Pharmed co. Iran) in the Treatmen · Phase 4 · recruiting
- NCT06426316 — The Role of Cytokines and Regulatory T Lymphocytes in Migraine Pathophysiology. · NA · recruiting
- NCT06623188 — Treatment of Episodic Migraine With AURICular Neuromodulation · NA · recruiting
- NCT06535880 — Trigeminal Brainstem Mapping 2: Higher Cortical Strucureas As Well As Subnuclei of the Spinal Trigeminal Nucleus · NA · recruiting
Other Quality Living, Inc. trials
Trials by the same sponsor.
- NCT06907381 — Blood Flow-restricted Resistance Exercise to Promote Muscle Strength and Use in Adults With Incomplete Spinal Cord Injur · enrolling by invitation
- NCT04369131 — Controlling Orthostatic Hypotension in People with Cervical Spinal Cord Injury · NA · withdrawn
- NCT03662243 — Treatment for Reading and Writing Deficits Following Acquired Brain Injury · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03662295 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Quality Living, Inc.
- Last refreshed: 10 March 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03662295.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing